Carla Meyer-Massetti

Summary

Affiliation: University of Basel
Country: Switzerland

Publications

  1. ncbi The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
    Carla Meyer-Massetti
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, Medication Outcomes Center, San Francisco, California, USA
    J Hosp Med 5:E8-16. 2010
  2. ncbi Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case
    Carla Meyer-Massetti
    Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
    Int J Clin Pharm 33:806-14. 2011

Collaborators

Detail Information

Publications2

  1. ncbi The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?
    Carla Meyer-Massetti
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, Medication Outcomes Center, San Francisco, California, USA
    J Hosp Med 5:E8-16. 2010
    ..We reviewed the evidence for the FDA warning and provide a potential medical center response to this warning...
  2. ncbi Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case
    Carla Meyer-Massetti
    Clinical Pharmacy and Epidemiology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
    Int J Clin Pharm 33:806-14. 2011
    ..Intravenous haloperidol is commonly used as a first line treatment for acute delirium. Consequently, the extended warning has caused uncertainty among health care professionals...